SAN DIEGO, November 13, 2024--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a ...

If the United States does not lead in emerging biotechnologies, our adversaries will, writes GOP Sen. Todd Young of Indiana.

Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today ...

Tharimmune (THAR) announced that the European Patent Office intends to grant the Company a patent covering biodegradable polymeric ...

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, ...

A Phase 1 SAD/MAD study of OV329 is progressing as planned, and based on encouraging human safety data to date, Ovid will ...

Tharimmune, Inc. (NASDAQ:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today ...

The global biological safety testing market size was US$ 4.1 billion in 2021. The global biological safety testing market is forecast to grow to US$ 10.8 billion by 2030 by registering a compound ...

Why do some people develop severe flu symptoms? A study points the finger at an unsung portion of the antibodies our immune systems generate to fend off invading pathogens.

Adipo Therapeutics LLC, a late-stage, preclinical biopharmaceutical company developing a potential treatment for obesity and ...

Jared Holz, Mizuho, joins 'Fast Money' to talk Viking Therapeutics and the biotech sector. YouTuber MrBeast becomes the 8th ...

a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. Receive News & Ratings for Oncternal Therapeutics Daily - ...